BeyondSpring (NASDAQ:BYSI) is a global biopharmaceutical company focused on the development of innovative cancer therapies. It is known for its work on creating advanced treatments aiming to improve outcomes for patients facing serious oncological challenges. The company's flagship project involves the drug Plinabulin, which is designed to prevent chemotherapy-induced neutropenia (CIN) - a common and serious side effect of cancer treatment. BeyondSpring is committed to advancing its pipeline of novel medications through clinical trials with the goal of bringing new therapies to market. The company's efforts are driven by a dedication to enhancing the lives of those affected by cancer through the delivery of effective and safer treatment options.